SPARSH BIO-TECH PVT LTD

Core Business Operations and Infrastructure

The company???s operations are centered around its state-of-the-art Pharmaceutical Formulation Unit, which is strategically located in an Export Processing Zone (EPZ) in Gujarat. This location and infrastructure support its business model as a dedicated manufacturer and exporter of medicinal products.

Manufacturing Focus: Betalactam Antibiotics A distinguishing feature of SPARSH BIO-TECH's manufacturing capability is its dedicated Betalactum building. This specialization is critical as it allows for the isolated and safe production of Betalactam antibiotics, which are a class of broad-spectrum antibiotics, including penicillins, vital for combating a wide range of bacterial infections. The facility is engineered to produce various dosage forms of these and other pharmaceutical products.

Quality and Compliance The company places a strong emphasis on maintaining high standards of quality throughout its production process. Their operations are guided by a commitment to delivering safe, effective, and cost-efficient medicines. The professional staff is trained to comply with cGMP (current Good Manufacturing Practices) before engaging in floor operations, and a system of quality inspectors ensures that all Standard Operating Procedures (S.O.P.) and Batch Manufacturing Record (B.M.R.) guidelines are strictly adhered to. This stringent quality management system underpins the reliability of their pharmaceutical offerings.

Products and Services

SPARSH BIO-TECH PVT LTD's product portfolio is comprehensive, focusing on finished pharmaceutical formulations for both human and veterinary applications. The primary dosage forms manufactured and offered by the company include:

• Capsules
• Tablets
• Dry Syrups and Oral Suspensions

The company's product line primarily focuses on antibiotics and anti-infective agents, utilizing key Active Pharmaceutical Ingredients (APIs) such as Penicillins and their derivatives, ampicillin, amoxicillin, cloxacillin, and phenoxymethylpenicillin.

Key Product Categories and Brands The company markets its products under various brand names, with a focus on anti-bacterial and general medicinal formulations:

| Product Brand Family | Primary API / Therapeutic Class | Dosage Forms Offered | | :--- | :--- | :--- | | CLOXISPA Products | Cloxacillin (a penicillinase-resistant penicillin) | Capsules, Oral Syrup | | SPAMOX Products | Amoxicillin (a moderate-spectrum ?-lactam antibiotic) | Capsules, Dispersible Tablets, Tablets | | SPAMCLOX Products | Ampicillin and Cloxacillin Combination | Capsules, Oral Syrup | | SPENIV Products | Phenoxymethylpenicillin (Penicillin V) | Tablets, Oral Syrup | | CO-FLUAMPICIL Products | Co-Fluampicil (combination of Flucloxacillin and Ampicillin) | Capsules, Oral Syrup | | General Formulations | Cefalexin, Amoxicillin | Capsules, Syrup, Tablets |

Specific Product Offerings Include:

• Pharmaceutical Tablets: Including Phenoxymethylpenicillin Tablets, Amoxicillin Tablets, and Speniv 250 Mg Tablets.
• Pharmaceutical Capsules: Such as Cloxispa Capsules, Co-fluampicil Capsules, and Amoxicillin Capsules.
• Oral Liquids/Syrups: Including Cefalexin Syrup, Spamclox Syrup (Ampicillin and Cloxacillin), Co-Fluampicil Oral Syrup, and Cloxacillin Oral Syrup.

Veterinary Medicines In addition to its human pharmaceutical line, SPARSH BIO-TECH also deals in Veterinary Medicines, demonstrating a broader commitment to health across sectors.

Market Position

The company, since its incorporation in 2001, has successfully navigated the complexities of the domestic and international pharmaceutical markets, including technical, regulatory, financial, and logistical challenges. Its dedicated manufacturing capabilities and focus on the high-demand Betalactam antibiotic segment position it as a significant manufacturer in the Indian pharmaceutical landscape. The firm's active status and substantial revenue generation???reported to be in the range of INR 100 cr to 500 cr for the financial year ending March 2024???underscore its established operational scale and market presence. Its status as an exporter further indicates a global outlook and adherence to international regulatory standards required for trade.